Your AI-Trained Oncology Knowledge Connection!

Julian Adams, PhD

Articles

$The DUO Trial: IPI-145 vs Ofatumumab in Relapsed or Refractory CLL or SLL$

The DUO Trial: IPI-145 vs Ofatumumab in Relapsed or Refractory CLL or SLL

August 28th 2014

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale behind the DUO trial.

$The DYNAMO Trial: IPI-145 for Refractory Indolent Non-Hodgkin Lymphoma$

The DYNAMO Trial: IPI-145 for Refractory Indolent Non-Hodgkin Lymphoma

Julian Adams, PhD

July 3rd 2014

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

An Overview of the Treatment of Hematologic Malignancies

Julian Adams, PhD

August 13th 2013

Julian Adams, PhD, from Infinity Pharmaceuticals, discusses PI3K inhibitors and chemotherapies for the treatment of hematologic malignancies.

The Phase I Trial of IPI-145 in Hematologic Malignancies

Julian Adams, PhD

June 21st 2013

Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3KEÎ´ and PI3K-Î³.